A Mechanism for the Upregulation of EGF Receptor Levels in Glioblastomas

Cell Reports

Volumn 3, Issue 6, 2013, Pages 2008-2020

  Zhang, Jingwen ^a   Antonyak, Marc A ^a   Singh, Garima ^a   Cerione, Richard A ^a  

^a Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ARTICLE; BINDING AFFINITY; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; MODELS, MOLECULAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84879800043     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.05.021     Document Type: Article

References (41)

1. Antonyak M.A., Kenyon L.C., Godwin A.K., James D.C., Emlet D.R., Okamoto I., Tnani M., Holgado-Madruga M., Moscatello D.K., Wong A.J. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 2002, 21:5038-5046.
2. Antonyak M.A., Miller A.M., Jansen J.M., Boehm J.E., Balkman C.E., Wakshlag J.J., Page R.L., Cerione R.A. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J.Biol. Chem. 2004, 279:41461-41467.
3. Antonyak M.A., Li B., Regan A.D., Feng Q., Dusaban S.S., Cerione R.A. Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J.Biol. Chem. 2009, 284:17914-17925.
4. Boroughs L.K., Antonyak M.A., Johnson J.L., Cerione R.A. A unique role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell migration. J.Biol. Chem. 2011, 286:37094-37107.
5. 2+)-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis. Biochemistry 2006, 45:13163-13174.
6. Datta S., Antonyak M.A., Cerione R.A. GTP-binding-defective forms of tissue transglutaminase trigger cell death. Biochemistry 2007, 46:14819-14829.
7. Frederick L., Wang X.Y., Eley G., James C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000, 60:1383-1387.
8. Furnari F.B., Lin H., Huang H.S., Cavenee W.K. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc. Natl. Acad. Sci. USA 1997, 94:12479-12484.
9. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., Hahn W.C., Ligon K.L., Louis D.N., Brennan C., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21:2683-2710.
10. Guillaudeau A., Durand K., Pommepuy I., Robert S., Chaunavel A., Lacorre S., DeArmas R., Bourtoumieux S., El Demery M., Moreau J.J., Labrousse F. Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent insitu hybridization. Appl. Immunohistochem. Mol. Morphol. 2009, 17:220-226.
11. Han W., Zhang T., Yu H., Foulke J.G., Tang C.K. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol. Ther. 2006, 5:1361-1368.
12. Hu J., Jo M., Cavenee W.K., Furnari F., VandenBerg S.R., Gonias S.L. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc. Natl. Acad. Sci. USA 2011, 108:15984-15989.
13. Huang P.H., Xu A.M., White F.M. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2009, 2:re6.
14. Jiang D., Ying W., Lu Y., Wan J., Zhai Y., Liu W., Zhu Y., Qiu Z., Qian X., He F. Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics 2003, 3:724-737.
15. Jiang W.G., Ablin R., Douglas-Jones A., Mansel R.E. Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol. Rep. 2003, 10:2039-2044.
16. Jung Y., Joo K.M., Seong D.H., Choi Y.L., Kong D.S., Kim Y., Kim M.H., Jin J., Suh Y.L., Seol H.J., et al. Identification of prognostic biomarkers for glioblastomas using protein expression profiling. Int. J. Oncol. 2012, 40:1122-1132.
17. Kim D.S., Choi Y.B., Han B.G., Park S.Y., Jeon Y., Kim D.H., Ahn E.R., Shin J.E., Lee B.I., Lee H., et al. Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking. Oncogene 2011, 30:4780-4790.
18. Layfield L.J., Willmore C., Tripp S., Jones C., Jensen R.L. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl. Immunohistochem. Mol. Morphol. 2006, 14:91-96.
19. Levkowitz G., Waterman H., Zamir E., Kam Z., Oved S., Langdon W.Y., Beguinot L., Geiger B., Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998, 12:3663-3674.
20. Li B., Antonyak M.A., Druso J.E., Cheng L., Nikitin A.Y., Cerione R.A. EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation. Proc. Natl. Acad. Sci. USA 2010, 107:1408-1413.
21. Li B., Cerione R.A., Antonyak M. Tissue transglutaminase and its role in human cancer progression. Adv. Enzymol. Relat. Areas Mol. Biol. 2011, 78:247-293.
22. Libermann T.A., Nusbaum H.R., Razon N., Kris R., Lax I., Soreq H., Whittle N., Waterfield M.D., Ullrich A., Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985, 313:144-147.
23. Liu S., Cerione R.A., Clardy J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc. Natl. Acad. Sci. USA 2002, 99:2743-2747.
24. Lund-Johansen M., Bjerkvig R., Humphrey P.A., Bigner S.H., Bigner D.D., Laerum O.D. Effect of epidermal growth factor on glioma cell growth, migration, and invasion invitro. Cancer Res. 1990, 50:6039-6044.
25. Miyoshi N., Ishii H., Mimori K., Tanaka F., Hitora T., Tei M., Sekimoto M., Doki Y., Mori M. TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer. Ann. Surg. Oncol. 2010, 17:967-972.
26. Mizoguchi M., Betensky R.A., Batchelor T.T., Bernay D.C., Louis D.N., Nutt C.L. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J.Neuropathol. Exp. Neurol. 2006, 65:1181-1188.
27. Moscatello D.K., Montgomery R.B., Sundareshan P., McDanel H., Wong M.Y., Wong A.J. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996, 13:85-96.
28. Pinkas D.M., Strop P., Brunger A.T., Khosla C. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007, 5:e327.
29. Qian X., Ren Y., Shi Z., Long L., Pu P., Sheng J., Yuan X., Kang C. Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. Mol. Pharm. 2012, 9:2636-2645.
30. Quaranta M., Divella R., Daniele A., Di Tardo S., Venneri M.T., Lolli I., Troccoli G. Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori 2007, 93:275-280.
31. Ren Y., Zhou X., Mei M., Yuan X.B., Han L., Wang G.X., Jia Z.F., Xu P., Pu P.Y., Kang C.S. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010, 10:27.
32. Rousselet E., Traver S., Monnet Y., Perrin A., Mandjee N., Hild A., Hirsch E.C., Zheng T.S., Hunot S. Tumor necrosis factor-like weak inducer of apoptosis induces astrocyte proliferation through the activation of transforming-growth factor-α/epidermal growth factor receptor signaling pathway. Mol. Pharmacol. 2012, 82:948-957.
33. Shinojima N., Tada K., Shiraishi S., Kamiryo T., Kochi M., Nakamura H., Makino K., Saya H., Hirano H., Kuratsu J., et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003, 63:6962-6970.
34. Singer C.F., Hudelist G., Walter I., Rueckliniger E., Czerwenka K., Kubista E., Huber A.V. Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer. Clin. Exp. Metastasis 2006, 23:33-39.
35. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N.Engl. J. Med. 2005, 352:987-996. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials GroupNational Cancer Institute of Canada Clinical Trials Group.
36. Umesh S., Tandon A., Santosh V., Anandh B., Sampath S., Chandramouli B.A., Sastry Kolluri V.R. Clinical and immunohistochemical prognostic factors in adult glioblastoma patients. Clin. Neuropathol. 2009, 28:362-372.
37. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. Cancer Genome Atlas Research Network.
38. Verma A., Wang H., Manavathi B., Fok J.Y., Mann A.P., Kumar R., Mehta K. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 2006, 66:10525-10533.
39. Vivanco I., Rohle D., Versele M., Iwanami A., Kuga D., Oldrini B., Tanaka K., Dang J., Kubek S., Palaskas N., et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc. Natl. Acad. Sci. USA 2010, 107:6459-6464.
40. Waterman H., Levkowitz G., Alroy I., Yarden Y. The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J.Biol. Chem. 1999, 274:22151-22154.
41. Weaver K.D., Yeyeodu S., Cusack J.C., Baldwin A.S., Ewend M.G. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J.Neurooncol. 2003, 61:187-196.